Aesthetic Performance and Tolerance of an Injective Intradermal Treatment for the Skin Roughness and Laxity of Back of the Hands
Skin Laxity, Skin Roughness
About this trial
This is an interventional treatment trial for Skin Laxity focused on measuring Skin laxity, Skin roughness, Profhilo Body, Hyaluronic Acid, Hybrid Cooperative Complexes
Eligibility Criteria
Inclusion Criteria: Will be included in the study volunteers with the following characteristics:
- female and male sex, not necessarily 1:1 ratio;
- age 18-65 years;
- asking for hands restoration;
- available and able to return to the study site for the post-procedural follow-up examinations;
- accepting to not change their habits regarding food, physical activity, cosmetic and cleansing products for the hands;
- accepting not to expose their hands to strong UV irradiation (UV session, or sun bathes) during the entire duration of the study, without appropriate sun protection;
Exclusion Criteria:
- Pregnancy;
- lactation;
- smokers;
- alcohol or drug abusers;
- subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study;
- Body Mass Index (BMI) variation (± 1) during the study period;
- performing non-surgical skin aesthetic procedures for hands in the 6 months prior to the study start;
- aesthetic surgical procedure for the hands in the past;
- change in the normal habits regarding food, physical activity, cosmetic products and cleansing for the hands during the month preceding the test;
- sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit);
- subjects whose insufficient adhesion to the study protocol is foreseeable;
- participation in a similar study currently or during the previous 6 months.)
- presence of cutaneous disease on the tested area, as lesions, scars, malformations;
- clinical and significant skin condition on the test area (e.g. active eczema, psoriasis, sclerodermia, local infections).
Exclusion criteria due to systemic disease:
- Diabetes;
- endocrine disease;
- hepatic disorder;
- renal disorder;
- cardiac disorder;
- pulmonary disease;
- cancer;
- neurological or psychological disease;
- inflammatory/immunosuppressive disease;
- drug allergy Exclusion criteria due to ongoing pharmacological treatment
- Anticoagulants and antiplatelet drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago);
- using of drugs able to influence the test results in the investigator opinion. The use of other drugs, not mentioned above, can be authorized by the Investigator. The trade name, the dosage, the start and stop date of the therapy will be reported on concomitant medication form.
Sites / Locations
- DERMING S.r.l., Clinical Research and Bioengineering Institute
Arms of the Study
Arm 1
Experimental
Profhilo® Body treatment group
1.5 ml per hand injected by a blunt tip microcannula (25G or 22G, preferably 22G), with fanning technique through a single entry point performing 5 passages and injecting 0,3 ml per passage. Day 0: Information and consent form provided. Clinical photography, Clinical assessment, Instrumental assessment, First treatment of Profhilo® (refer to study protocol). Day 30 (1 month after day 0): Clinical photography, Clinical assessment, Instrumental assessment, Second treatment of Profhilo® (refer to study protocol), Self-evaluation questionnaire. Day 120 (4 months after day 0): Clinical photography, Clinical assessment, Instrumental assessment, NO treatment, Self-evaluation questionnaire.